Orbis Medicines

News

Aviceda raises $207.5m for eye drug, and other financings

Our round-up of recent biotech financings includes a big round for Aviceda, with Orbis, Alebund, XyloCor, and PrimeGene also raising additional cash.

News

BioMarin ends year with $4.8bn play for Amicus

BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks